Eiken Chemical
4549.TTSE PRIMEPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥41.9bn | ¥40.5bn | ¥40.1bn | ¥43.3bn | ¥43.0bn | ¥38.7bn |
| Operating income | ¥2.9bn | ¥3.0bn | ¥3.4bn | ¥7.5bn | ¥8.4bn | ¥6.6bn |
| Ordinary income | ¥2.8bn | ¥3.2bn | ¥3.6bn | ¥7.6bn | ¥8.5bn | ¥6.8bn |
| Net income (owners) | ¥3.7bn | ¥2.2bn | ¥2.6bn | ¥5.7bn | ¥6.2bn | ¥5.0bn |
| Total assets | ¥62.7bn | ¥62.4bn | ¥61.7bn | ¥66.3bn | ¥62.5bn | ¥55.7bn |
| Net assets / equity | ¥44.0bn | ¥43.6bn | ¥46.0bn | ¥49.5bn | ¥45.8bn | ¥41.7bn |
| Operating cash flow | ¥4.0bn | ¥6.0bn | ¥3.8bn | ¥7.6bn | ¥7.8bn | ¥5.5bn |
| EPS (basic) | ¥112.52 | ¥64.82 | ¥71.69 | ¥155.17 | ¥168.28 | ¥136.65 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 206 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 206 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 70 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 206 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 70 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 206 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 48 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 72 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 46 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 206 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 48 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 72 figures · EDINET |
| 2017-04-01 → 2018-03-31 | AnnualAmended | 204 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 46 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 206 figures · EDINET |
21 more reports are still being processed.